Select trials of novel agents in R/R HL
| Regimen . | n . | ORR (%) . | CRR (%) . | Median PFS . |
|---|---|---|---|---|
| Brentuximab vedotin2 | 102 | 75 | 33 | 5.6 mo |
| Nivolumab9 | 243 | 69 | 16 | 14.7 mo |
| Pembrolizumab10 | 210 | 69 | 22 | 13.7 mo |
| ADCT-30131 | 60 | 69 | 44 | Not reported |
| Lenalidomide34 | 38 | 19 | 3 | 4 mo |
| Everolimus37 | 57 | 42 | 8 | 9 mo |
| Panobinostat35 | 129 | 23 | 4 | 6.1 mo |
| Idelalisib36 | 25 | 20 | 4 | 2.3 mo |
| Combination regimens | ||||
| Nivolumab + ipilimumab28 | 31 | 74 | 19 | Not reached after 11.4 mo |
| BV + nivolumab + ipilimumab29 | 22 | 82 | 68 | Not reached after 6 mo |
| Pembrolizumab + AFM-1330 | 30 | 87 | 39 | Not reported |
| Regimen . | n . | ORR (%) . | CRR (%) . | Median PFS . |
|---|---|---|---|---|
| Brentuximab vedotin2 | 102 | 75 | 33 | 5.6 mo |
| Nivolumab9 | 243 | 69 | 16 | 14.7 mo |
| Pembrolizumab10 | 210 | 69 | 22 | 13.7 mo |
| ADCT-30131 | 60 | 69 | 44 | Not reported |
| Lenalidomide34 | 38 | 19 | 3 | 4 mo |
| Everolimus37 | 57 | 42 | 8 | 9 mo |
| Panobinostat35 | 129 | 23 | 4 | 6.1 mo |
| Idelalisib36 | 25 | 20 | 4 | 2.3 mo |
| Combination regimens | ||||
| Nivolumab + ipilimumab28 | 31 | 74 | 19 | Not reached after 11.4 mo |
| BV + nivolumab + ipilimumab29 | 22 | 82 | 68 | Not reached after 6 mo |
| Pembrolizumab + AFM-1330 | 30 | 87 | 39 | Not reported |